Author: Kathryn Atkins

Figure 8: Major analytical performance measurements of the NeXT Personal® assay.

Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal®

March 20, 2024

“These results suggest strong potential for clinical use of the assay in ctDNA monitoring of solid tumor cancers.” BUFFALO, NY- March 20, 2024 – A new research paper was published… read more

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.” BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,… read more

Figure 2: A comparative analysis of G4 landscape in cultured cells using AbC G4-ChIP. antibody

Oncotarget

A New Antibody Capture Method Reveals G-quadruplex Landscape and its Regulation

March 18, 2024

“[...] we present an improved method for G4 landscape determination and by applying it we show that sequence property-specific constraints of the nuclear environment mitigate G4 formation.” BUFFALO, NY- March… read more

Oncotarget

Oncotarget at AACR Annual Meeting 2024

March 11, 2024

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of… read more

Figure 7: ER stress signaling plays an important role in mediating GZ17-6.02/bortezomib lethality

Oncotarget

GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells

March 6, 2024

“We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities to develop therapeutic approaches which will prolong patient survival.” BUFFALO, NY-… read more

Figure 2: Immunoblot assessment of effects on cell-cycle, pro- and anti-apoptosis signaling events mediated by Sacituzumab govitecan plus platinum-based chemotherapeutics in human TNBC, SCLC, and UBC tumor-lines.

Oncotarget

Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas

March 4, 2024

“[...] these results support the rationale and potential for favorable clinical outcomes of combining SG therapy with platinum-based chemotherapeutics in solid tumors.” BUFFALO, NY- March 4, 2024 – A new… read more

Oncotarget

BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula

February 28, 2024

“Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological… read more

Figure 7: Combined macroautophagy and CD95 death receptor signaling facilitate additional tumor cell killing by GZ17-6.02

Oncotarget

GZ17-6.02 With Bexarotene Kills Mycosis Fungoides Cells

February 26, 2024

“The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell types,… read more

Figure 1: From genome-wide CRISPR screen to the creation of combined predicting models.

Oncotarget

Combining Causal and Correlative Approaches to Discover Response Biomarkers to Paclitaxel

February 21, 2024

“The discovery of predictive biomarkers to paclitaxel vulnerability [such] as SSR3 [signal sequence receptor 3] promises to significantly impact cancer treatment.” BUFFALO, NY- February 21, 2024 – A new research… read more

Figure 1: Flowchart depicting patient selection.

Oncotarget

NTRK Gene Fusion in Papillary Thyroid Cancer: A Clinicogenomic Biobank and Record Linkage Study From Finland

February 19, 2024

“Estimates of the frequency of NTRK gene fusion in large cohorts of patients with solid tumors come from a limited number of studies. [...]. We aimed to address this gap… read more